The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.
Antigens, Neoplasm
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Cancer Vaccines
/ immunology
Cells, Cultured
Colorectal Neoplasms
/ immunology
Drug Design
Epitopes
/ immunology
HLA-DR Antigens
/ immunology
Humans
Interferon-gamma
/ immunology
Peptides
/ immunology
T-Lymphocytes
/ immunology
T-Lymphocytes, Regulatory
/ immunology
Th1 Cells
/ immunology
5T4
Antigen specificity
Cancer
Regulatory T cells
T cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
23
04
2018
accepted:
19
10
2018
pubmed:
9
11
2018
medline:
26
2
2019
entrez:
9
11
2018
Statut:
ppublish
Résumé
The oncofoetal antigen 5T4 is a promising T cell target in the context of colorectal cancer, as demonstrated by a recent clinical study where 5T4-specific T cell responses, induced by vaccination or cyclophosphamide, were associated with a significantly prolonged survival of patients with metastatic disease. Whilst Th1-type (IFN-γ
Identifiants
pubmed: 30406375
doi: 10.1007/s00262-018-2266-1
pii: 10.1007/s00262-018-2266-1
pmc: PMC6394487
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Epitopes
0
HLA-DR Antigens
0
Peptides
0
oncofetal antigens
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-256Subventions
Organisme : Wellcome Trust
ID : 209213/Z/17/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 21200
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C16731/A21200
Pays : United Kingdom
Références
Tissue Antigens. 2003 Oct;62(4):296-307
pubmed: 12974796
Br J Cancer. 1992 Nov;66(5):867-9
pubmed: 1419629
Immunity. 2004 Jan;20(1):107-18
pubmed: 14738769
J Immunol. 2006 Aug 15;177(4):2717-27
pubmed: 16888034
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
J Immunol. 1991 Oct 15;147(8):2663-9
pubmed: 1717570
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92
pubmed: 17615234
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20884-9
pubmed: 18093940
Clin Cancer Res. 2008 Jan 1;14(1):178-87
pubmed: 18172269
Blood. 2008 Oct 15;112(8):3303-11
pubmed: 18660382
J Exp Med. 2008 Oct 27;205(11):2673-82
pubmed: 18936238
Adv Drug Deliv Rev. 2009 Sep 30;61(11):965-76
pubmed: 19619593
BMC Bioinformatics. 2009 Sep 18;10:296
pubmed: 19765293
J Clin Invest. 2009 Nov;119(11):3311-21
pubmed: 19809157
Int J Cancer. 2010 Aug 15;127(4):759-67
pubmed: 20518016
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9
pubmed: 20547850
Cancer Immunol Immunother. 2011 Mar;60(3):327-37
pubmed: 21080167
Cancer Sci. 2011 Aug;102(8):1455-61
pubmed: 21595801
Gut. 2012 Aug;61(8):1163-71
pubmed: 22207629
PLoS One. 2012;7(10):e48424
pubmed: 23110239
PLoS One. 2012;7(12):e51716
pubmed: 23284752
Br J Cancer. 1990 Jan;61(1):89-95
pubmed: 2404511
Mucosal Immunol. 2014 Mar;7(2):428-39
pubmed: 24064667
Cancer Immunol Res. 2013 Dec;1(6):null
pubmed: 24409450
Front Immunol. 2014 Apr 15;5:174
pubmed: 24782871
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
Hum Immunol. 2014 Dec;75(12):1139-46
pubmed: 25454619
Oncoimmunology. 2015 Jun 5;4(7):e1058597
pubmed: 26140250
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6192-E6198
pubmed: 27681619
JAMA Oncol. 2017 Oct 12;3(10):e172579
pubmed: 28880972
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146